The Immunometabolic Nexus of Neurodegeneration: Autophagic Failure, Microglial Senescence, and Periphery-Driven Rescue Mechanisms

Abstract

Neurodegenerative disorders, encompassing Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS), have historically been conceptualized as cell-autonomous pathologies driven by neuronal protein misfolding and aggregation. However, emerging evidence necessitates a paradigm shift toward a systemic, immunometabolic framework. This doctoral-level thesis critically examines the profound reciprocal relationship between autophagic failure and neuroinflammation, positioning microglia—the resident innate immune cells of the central nervous system (CNS)—as both victims and vectors of neurodegenerative cascades. Microglial autophagic dysfunction not only impairs the clearance of toxic protein aggregates but also precipitates a hyper-inflammatory state via the hyperactivation of the NLRP3 inflammasome. In a devastating non-cell-autonomous feedback loop, the resulting microglial secretome, heavily laden with pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α), subsequently suppresses autophagic flux in neighboring neurons via the AKT/mTOR signaling pathway.

As pathology progresses, the continuous exposure to an overwhelmed proteostatic environment drives microglia into a state of irreversible cellular senescence. Characterized by metabolic reprogramming, lipid accumulation, and a senescence-associated secretory phenotype (SASP), these senescent microglia abandon their neuroprotective roles. The pathological footprint of autophagic failure extends far beyond microglia, inducing catastrophic vulnerabilities in neuronal sub-structures—such as axonal transport systems and lysosomal networks—as well as compromising astrocytes, oligodendrocytes, and the endothelial cells of the blood-brain barrier. To counteract this multifaceted systemic collapse, the pioneering neuroimmunological framework developed by Michal Schwartz and colleagues introduces peripheral immune rejuvenation as a viable therapeutic intervention. By demonstrating that systemic bone marrow myelopoiesis is compromised by chronic type I interferon (IFN-I) signaling in AD, this approach utilizes PD-1/PD-L1 immune checkpoint blockade to break the cycle of immune exhaustion. This systemic intervention facilitates the clearance of senescent microglia and recruits highly functional, monocyte-derived macrophages (MDMs) from the periphery into the brain, effectively restoring homeostatic clearance mechanisms and arresting cognitive decline.

Prepared for Dr. James Truchard and Benjamin Gustafsson
Drafted by ChatGPT-5.2

Introduction

The maintenance of homeostasis within the central nervous system (CNS) requires an exquisite equilibrium between the generation of cellular components and their degradation. At the heart of this equilibrium is autophagy, an evolutionarily conserved, lysosome-dependent degradation pathway responsible for the clearance of damaged organelles, misfolded proteins, and intracellular pathogens.[1] Autophagy operates through three primary mechanisms: macroautophagy, which involves the sequestration of cytosolic components within double-membraned autophagosomes; microautophagy, characterized by the direct invagination of the lysosomal membrane; and chaperone-mediated autophagy (CMA), a highly selective process utilizing molecular chaperones for targeted protein degradation.[3] While the post-mitotic nature of neurons renders them uniquely dependent on robust autophagic flux to prevent the accumulation of neurotoxic aggregates over a lifespan, recent neuroimmunological research has fundamentally expanded this view. It is now evident that the autophagic capacity of glial cells, particularly microglia, is equally critical to the survival of the neural parenchyma.[3]

Microglia constitute approximately 10% of the cellular population in the CNS and serve as its primary innate immune sentinels.[6] Arising from the embryonic yolk sac during early development, these cells form a self-renewing population that operates independently of peripheral hematopoiesis under physiological conditions.[7] Under these normal conditions, they continuously survey the microenvironment, pruning synapses, maintaining the integrity of the blood-brain barrier (BBB), and clearing cellular debris through closely integrated phagocytic and autophagic mechanisms.[3] However, in the context of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), the microglial network frequently fails.[3] This failure is not merely a passive bystander effect but an active driver of pathology. The disruption of microglial autophagy initiates a vicious cycle of neuroinflammation and proteostasis collapse, ultimately leading to a state of microglial senescence.[3]

The transition of microglia from protective sentinels to toxic agents represents a critical juncture in disease progression. This thesis investigates the intricate, bidirectional relationship between microglial autophagy failure and neuronal degeneration. It seeks to rigorously answer several interconnected questions that are paramount to contemporary neurobiology: What drives the failure of autophagy in microglia, and how does this failure non-cell-autonomously paralyze neuronal autophagy? What are the precise molecular and metabolic triggers that force microglia into a state of irreversible cellular senescence? Furthermore, how do peripheral immune interventions, particularly the systemic PD-L1 blockade championed by Michal Schwartz, rescue the CNS by leveraging monocyte-derived macrophages (MDMs)? Finally, this report maps the broader landscape of autophagic vulnerability across the brain, detailing how neurons, astrocytes, oligodendrocytes, and vascular endothelial cells succumb to the collapse of lysosomal and autophagic networks.

Through addressing these questions, this thesis underscores a vital conceptual shift:

neurodegenerative diseases must be understood and treated not as isolated proteinopathies of the brain, but as systemic immunometabolic disorders wherein the failure of intracellular clearance mechanisms directly dictates the collapse of neuro-immune cross-talk.

Literature Review

The historiography of neurodegenerative disease research reflects a fascinating evolution of scientific paradigms, shifting from anatomical observations to molecular genetics, and most recently, to systemic immunology. Historically, the pathogenesis of neurodegenerative diseases was dominated by the amyloid cascade hypothesis and related protein-centric theories. Following Alois Alzheimer's initial documentation of senile plaques and neurofibrillary tangles in the early 20th century [10], late-20th-century molecular biology firmly established amyloid-beta (Aβ) and hyperphosphorylated tau as the principal pathological hallmarks of AD, while alpha-synuclein (α-syn) was identified in PD.[10] These models posited that the overproduction or decreased clearance of these specific proteins were the primary, cell-autonomous instigators of neuronal apoptosis. Consequently, the pharmaceutical industry invested billions of dollars in immunotherapies designed to clear amyloid plaques. While the toxicity of these aggregates is undisputed, therapies exclusively targeting these proteins have faced decades of clinical failures, prompting the field to re-evaluate the underlying mechanisms of disease progression.[10]

The advent of high-dimensional single-cell transcriptomics catalyzed a paradigm shift, revealing that the immune system plays a determinative role in neurodegeneration. A major breakthrough was the identification of "disease-associated microglia" (DAM), a transcriptionally distinct microglial state that localizes around amyloid plaques and actively attempts to phagocytose Aβ.[3] The genomic revolution further supported this microgliocentric view. Genome-wide association studies (GWAS) identified that the vast majority of risk loci for late-onset AD—including APOE, TREM2, CD33, and CR1—are highly expressed in, or exclusive to, microglia and myeloid cells.[8] The DAM phenotype, specifically, was found to be heavily dependent on the Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) pathway.[8] Initially, the field hypothesized that pharmacologically enhancing the DAM state could provide a definitive cure. However, longitudinal studies demonstrated that as the disease progresses, the DAM response is fundamentally finite.[12] Overwhelmed by chronic exposure to misfolded proteins, microglia undergo metabolic exhaustion and shift from a protective DAM state to a dysfunctional, senescent state.[14]

Simultaneously, the study of autophagy evolved from a strictly neuronal focus to encompass glial metabolism. Early autophagy research in the CNS primarily documented the accumulation of autophagosomes in dystrophic neurites.[16] However, recent scholarship established that microglial autophagy is intrinsically linked to the regulation of the inflammatory response.[1] It became clear that the impairment of autophagic flux within microglia directly unleashes the NLRP3 inflammasome, leading to the unregulated secretion of pro-inflammatory cytokines.[3]

This established a new theoretical model: neuroinflammation is not merely a reaction to cell death, but a direct consequence of intracellular clearance failure.

The most recent and perhaps most transformative theoretical development in this domain has been the recognition that neurodegeneration is inextricably linked to systemic, peripheral immune failure. Pioneered largely by Michal Schwartz and her contemporaries, this framework argues that the brain is not an absolutely immune-privileged site isolated from systemic biology.[18] Instead, the CNS relies on continuous, well-regulated cross-talk with the peripheral immune system, primarily via the choroid plexus and meningeal lymphatic networks.[20] Schwartz posited that the brain requires assistance from circulating T cells and monocytes for repair and maintenance. In aging and neurodegenerative states, this peripheral support system collapses. Schwartz's work theoretically repositions neurodegenerative disease as a systemic immunometabolic failure, proposing that the ultimate rescue of the CNS requires the rejuvenation of peripheral immune cells, specifically circulating monocytes, to reinforce the exhausted resident microglia.[7] This thesis intervenes in these intersecting discourses by synthesizing the intracellular mechanics of autophagy with the macroscopic dynamics of systemic immunity, proving that microglial senescence is the anatomical bridge between autophagic failure and systemic immune exhaustion.

Analytical Framework and Disciplinary Approach

To systematically interrogate the intersection of autophagy, microglial senescence, and peripheral immune rescue, this thesis employs a systems immunology approach. This framework rejects the historical isolation of the CNS, analyzing the brain, its barriers (such as the blood-brain barrier and the choroid plexus), and the peripheral immune system (including the bone marrow and spleen) as a single, contiguous biological network.

The analytical synthesis relies on data derived from multiple advanced methodologies documented in contemporary neuroimmunological literature. A central component of this analysis is the interpretation of single-cell RNA sequencing (scRNA-seq) and Cellular Indexing of Transcriptomes and Epitopes by Sequencing (CITE-seq) data. These high-resolution transcriptomic tools are utilized to differentiate the genetic signatures of homeostatic microglia, disease-associated microglia (DAM), senescence-associated microglia (SAM), and infiltrating monocyte-derived macrophages (MDMs).[7] By analyzing the expression of specific clusters—such as the upregulation of inflammatory markers (IL-1β, TNF-α) versus phagocytic scavenger receptors (MSR1, MRC1)—the functional capacities of these distinct myeloid populations can be accurately mapped.

Furthermore, this analysis relies heavily on high-throughput mass cytometry (CyTOF) utilized in recent literature to phenotype senescent microglia and track the expression of surface markers such as TREM2, PD-L1, and various senescence indicators at the single-cell protein level.[25] The integration of these proteomic and transcriptomic datasets allows for a multidimensional

understanding of cellular states during the progression of neurodegeneration.

In evaluating the in vivo mechanics of disease, this report analyzes findings from several sophisticated transgenic murine models that are foundational to the field. The 5xFAD model of amyloidosis is heavily referenced to understand the rapid accumulation of Aβ and the subsequent microglial response, as well as the transition into senescence.[7] The PS19 (P301S) tauopathy model is examined to assess the impact of intracellular tau tangles on autophagic flux and the efficacy of immune checkpoint blockade in aggressively progressing pathologies.[7] Additionally, the AppNL-G-FxMAPT double knock-in mice are utilized to map spatial vulnerabilities, specifically regarding the localized failure of autophagy in hypothalamic sleep-wake neurons prior to overt plaque deposition.[27]

By synthesizing in vitro autophagic flux assays (e.g., tracking the LC3-II to p62/SQSTM1 ratio) with in vivo behavioral outcomes (such as spatial memory tests in the Barnes maze or Novel Object Recognition tasks) and histological evaluations, this approach ensures that the molecular mechanisms of autophagic failure are rigorously correlated with systemic neuroinflammatory profiles and cognitive decline. This comprehensive, multi-layered methodology grounds the theoretical claims of the thesis in robust, empirical biological data.

Chapter 1: The Reciprocal Dynamics of Autophagy Failure in Microglia and Neurons

The architecture of neurodegeneration is built upon a catastrophic failure of clearance mechanisms. While neuronal autophagy failure has long been recognized as a driver of proteinopathy, recent data elucidates a complex, non-cell-autonomous relationship wherein microglial autophagy failure accelerates neuronal collapse, and reciprocally, neuronal pathology drives microglial exhaustion.

Cell-Autonomous Autophagy Failure in Microglia

Microglia rely on canonical macroautophagy and closely related processes like LC3-associated phagocytosis (LAP) and LC3-associated endocytosis (LANDO) to degrade extracellular and intracellular threats.[3] In neurodegenerative contexts, microglia actively internalize neurotoxic aggregates. For instance, microglia engage in "synucleinphagy," a targeted autophagic process utilizing Toll-like receptor 4 (TLR4) signaling and NF-κB-driven p62 induction to clear neuron-released α-synuclein.[3] Similarly, they phagocytose Aβ and attempt to degrade it within autolysosomes.

However, chronic exposure to these aggregates eventually overwhelms the microglial lysosomal machinery. Prolonged exposure to Aβ peptides (specifically extending beyond 24 hours) induces severe lysosomal damage, leading to the accumulation of autophagic vesicles and a subsequent, sharp reduction in autophagic flux.[30] The failure of microglial autophagy has immediate and severe inflammatory consequences. Autophagy fundamentally serves as a

negative regulator of the NLRP3 inflammasome—a cytosolic multiprotein oligomer responsible for the maturation and secretion of highly inflammatory cytokines.[3] Under healthy conditions, autophagy removes the endogenous triggers of inflammasome activation. However, when autophagic flux is blocked, damaged mitochondria begin to accumulate due to impaired mitophagy. These dysfunctional mitochondria leak mitochondrial reactive oxygen species (mtROS) and mitochondrial DNA (mtDNA) into the microglial cytosol.[5]

This cytosolic leakage acts as a potent trigger for NLRP3 inflammasome assembly. The resulting activation of caspase-1 leads to the unregulated cleavage and massive release of interleukin-1β (IL-1β) and interleukin-18 (IL-18).[28] Consequently, the microglial cell is locked into a hyper-inflammatory, M1-like polarization state, abandoning its tissue-repair functions in favor of a sustained, cytotoxic immune response.[33]

The Non-Cell Autonomous Impact: Microglia Paralyzing Neuronal Autophagy

The transition of microglia into an autophagic-deficient, pro-inflammatory state has devastating downstream effects on neuronal proteostasis. The microglial secretome, heavily concentrated with cytokines, actively suppresses the autophagic machinery in neighboring neurons, creating a lethal feed-forward loop.[35]

The primary mechanism for this non-cell-autonomous suppression is mediated by Tumor Necrosis Factor-alpha (TNF-α). When microglia secrete high levels of TNF-α in response to their own internal autophagic blockage, this cytokine binds to receptors on adjacent neurons. The binding of TNF-α activates the neuronal AKT/mTOR (mechanistic target of rapamycin) signaling pathway.[33] The mTOR kinase serves as the master negative regulator of macroautophagy. Under normal physiological conditions, the inhibition of mTOR allows the ULK1 complex to initiate phagophore formation, kicking off the autophagic process. However, the continuous, pathological activation of the AKT/mTOR axis by microglial TNF-α chronically phosphorylates and suppresses ULK1, effectively halting neuronal autophagic flux.[33]

The suppression of neuronal autophagy means that neurons can no longer clear their own internally generated Aβ, hyperphosphorylated tau, or α-synuclein. This accelerates intracellular toxicity, leading to the formation of neurofibrillary tangles and the eventual execution of apoptotic cascades. This creates a vicious cycle: neurons dying from autophagic arrest release more toxic aggregates into the extracellular space, which further damages microglial lysosomes, leading to more TNF-α release, thereby paralyzing more neurons.

The Reciprocal Cycle of Autophagic Failure in Neurodegeneration



Misfolded proteins trigger microglial autophagy failure, leading to NLRP3 inflammasome activation and the release of TNF-α. This cytokine activates the neuronal AKT/mTOR pathway, suppressing neuronal autophagy and exacerbating protein aggregation.

Tunneling Nanotubes (TNTs) and the Failure of Transfer

Another fascinating dimension of this reciprocal relationship involves direct physical connections between cells known as tunneling nanotubes (TNTs). Under physiological conditions, healthy microglia extend F-actin-rich TNTs to burdened neurons. These microscopic conduits act as a relief valve, allowing microglia to physically extract toxic aggregates (such as α-synuclein) from the neuron for degradation within the highly efficient microglial lysosomal network.[29] Furthermore, microglia can use these conduits in the opposite direction to donate healthy mitochondria to dying neurons, rescuing them from oxidative stress and restoring bioenergetic homeostasis.[37]

However, when microglial autophagy is compromised, this brilliant rescue mechanism becomes a devastating liability. Microglia with impaired lysosomes and halted autophagic flux cannot efficiently degrade the aggregates they receive via TNTs.[38] Consequently, the aggregates accumulate within the microglial cytoplasm. Because the structural integrity of the TNTs often remains intact even as degradation fails, the TNT network inadvertently facilitates the bidirectional, prion-like spread of pathology, acting as a vector for the dissemination of

α-synuclein and tau throughout the broader brain parenchyma.[29] What evolved as a mechanism for neuroprotection is thus hijacked into a mechanism of disease propagation.

Chapter 2: The Etiology and Phenotypic Architecture of Microglial Senescence

As the neurodegenerative state becomes chronic, the persistent failure of autophagy and relentless inflammatory signaling drive microglia past the point of mere dysfunction into an irreversible state of cellular senescence. Cellular senescence is defined as a state of stable cell cycle arrest coupled with profound phenotypic alterations. In the context of AD, senescent microglia abandon their reparative roles, transitioning from protective Disease-Associated Microglia (DAM) into detrimental Senescence-Associated Microglia (SAM).[9]

The Drivers of Senescence

Cellular senescence in microglia is not solely a product of chronological aging; it is an active, stress-induced response to a hostile microenvironment. A primary trigger is the collapse of the autophagic machinery itself. Experimental genetic ablation of essential autophagy genes (e.g., Atg5 or Atg7) in microglial models directly precipitates cell cycle arrest, dystrophic morphologies, and the onset of senescence.[9] When deprived of their ability to dispose of intracellular detritus, microglia effectively shut down, demonstrating that autophagic integrity is an absolute prerequisite for maintaining the DAM state.[12]

Beyond autophagic collapse, chronic exposure to type I interferon (IFN-I) signaling serves as a massive catalyst for senescence. In AD, widespread mitochondrial dysfunction leads to the leakage of mtDNA into the cytosol. This is detected by the cGAS-STING (cyclic GMP-AMP synthase – stimulator of interferon genes) pathway, which triggers massive, sustained IFN-I production.[31] This chronic IFN-I signaling loop induces the suppression of myocyte-specific enhancer factor 2C (MEF2C), a critical microglial "off-switch" that normally restrains inflammatory responses. The loss of MEF2C locks the cells into a degenerative, aged, and hyper-reactive phenotype.[31]

Furthermore, senescence is driven by severe metabolic dysregulation. As microglia age and face chronic pathology, they undergo a metabolic shift away from efficient oxidative phosphorylation (OXPHOS) and become entirely reliant on glycolysis.[31] This metabolic reprogramming drastically reduces their ATP yield and severely limits their capacity for energy-intensive processes like phagocytosis. This metabolic failure is accompanied by the inability to process phagocytosed myelin and cellular lipid debris, leading to the massive intracellular accumulation of lipid droplets. These lipid-droplet-accumulating microglia (LDAM) are a pathological hallmark of the senescent state, exhibiting profound deficits in clearance activities and a heightened propensity for releasing reactive oxygen species.[14]

Biomarkers and the TREM2 Paradox

The identification of senescent microglia in vivo relies on a combinatorial approach, as no single marker is entirely exclusive to the state. Classic cellular hallmarks include the pronounced expression of cyclin-dependent kinase inhibitors, specifically p16 (CDKN2A) and p21 (CDKN1A), which force the cell out of the replication cycle.[42] This is typically measured alongside increased senescence-associated beta-galactosidase (SA-β-gal) activity, a traditional indicator of lysosomal expansion and dysfunction.[43]

A defining functional characteristic of these cells is the Senescence-Associated Secretory Phenotype (SASP). Instead of remaining quiescent after cell cycle arrest, senescent microglia continuously secrete a toxic cocktail of inflammatory mediators, including IL-6, IL-1β, and TNF-α, which actively poison the surrounding neural tissue and exacerbate astrocytic and neuronal damage.[43] Additionally, senescent microglia exhibit severe iron dyshomeostasis, marked by the aberrant accumulation of ferritin within the cytoplasm, leading to increased oxidative stress and potential ferroptosis resistance.[41]

Biomarker Category	Specific Markers / Observations	Pathological Role in Senescent Microglia
Cell Cycle Arrest	p16 (CDKN2A), p21 (CDKN1A)	Halts cellular proliferation; forces permanent exit from the cell cycle, preventing microglial self-renewal.[43]
Enzymatic Activity	SA-β-gal	Classical indicator of expanded, dysfunctional lysosomal compartments.[43]
Metabolic / Storage	Lipid droplets, Lipofuscin, Ferritin	Indicates failure of lipid metabolism (LDAM) and iron dyshomeostasis, driving internal oxidative stress.[41]
Secretory Phenotype	SASP (IL-6, IL-1β, TNF-α)	Chronic release of inflammatory cytokines that exacerbate non-cell-autonomous neurotoxicity.[43]

Surface Receptors	Paradoxically High TREM2	Uncoupled from normal phagocytic signaling; aberrantly supports the survival of the senescent cell.[15]

The role of TREM2 in this context represents one of the most complex biological paradoxes in modern neuroimmunology. In the early stages of AD, TREM2 is absolutely vital for the protective DAM response; it senses lipids, promotes the encapsulation and compaction of amyloid plaques, and sustains microglial survival.[8] Consequently, loss-of-function mutations in TREM2 (such as R47H) significantly increase the risk of AD.[13]

Conversely, recent high-throughput mass cytometry studies have revealed that senescent microglia in advanced AD models paradoxically express *extremely high* levels of TREM2.[26] However, in these senescent cells, the TREM2 signaling axis appears fundamentally uncoupled from its protective phagocytic functions. Instead of facilitating the clearance of plaques, the sustained, dysfunctional TREM2 signaling acts as a survival factor for the senescent cell itself. It prevents the apoptotic clearance of these exhausted cells, allowing them to persist in the brain parenchyma as toxic, SASP-secreting entities.[15] This dual nature of TREM2—protective early on, but pathogenic when coupled with senescence—severely complicates therapeutic strategies aimed at blindly agonizing the TREM2 receptor in late-stage disease.

Chapter 3: Expanding the Radius of Vulnerability: Axons, Synapses, Glia, and the BBB

The collapse of the autophagic-lysosomal network is not isolated to the microglial compartment. The entire neuro-glial-vascular syncytium is highly vulnerable to autophagic failure, with the pathology manifesting in distinct, cell-type-specific structural and functional deficits.

Neuronal Sub-Cellular Vulnerabilities: Axons, Synapses, and Lysosomes

Neurons are uniquely susceptible to autophagic failure due to their extreme spatial polarization and post-mitotic status. Unlike dividing cells, which can dilute toxic aggregates during mitosis, neurons must rely entirely on internal clearance mechanisms over an organism's lifetime.[2] The logistical demands of neuronal autophagy are immense. Autophagosomes are typically generated in the distal axon terminals and must be retrogradely transported along the entire length of the axon via dynein motor complexes to fuse with lysosomes located in the soma.[11] In neurodegenerative states, this fragile transport system fails. Impaired retrograde transport leads to massive traffic jams of autophagosomes and endosomes within the axon, creating the

axonal spheroids and dystrophic neurites characteristic of AD and PD pathology.[16]

At the synapse, localized autophagy is strictly required for the turnover of synaptic vesicles and the degradation of postsynaptic receptors (such as AMPA receptors) to facilitate synaptic plasticity, memory destabilization, and network refinement.[51] The local recruitment of autophagy-related proteins (e.g., ATG3) is mediated by synaptic proteins like Endophilin A (EndoA).[52] Failure of synaptic autophagy directly leads to structural synaptic abnormalities, the accumulation of worn organelles, and severe network hyperexcitability, frequently preceding overt neuronal death and driving the epileptic phenotypes sometimes observed in dementia models.[51]

Furthermore, the lysosomes themselves become sites of catastrophic failure. In AD, the accumulation of Aβ and its precursor fragments (such as APP-βCTF) within the lysosome directly impairs the v-ATPase proton pump.[2] This leads to profound lysosomal deacidification, rendering the resident acidic hydrolases inactive. The resulting build-up of undegraded material stretches the lysosomal membrane, eventually causing Lysosomal Membrane Permeabilization (LMP). LMP leaks highly toxic cathepsins and reactive iron (from degraded ferritin) into the cytosol, inducing oxidative stress and ferroptosis.[2] In the most vulnerable neuronal populations, this failure manifests as PANTHOS (poisonous flower)—a morphological anomaly where the neuronal soma becomes massively engorged with poorly acidified autolysosomes that bulge outward in large, petal-like blebs.[54] These PANTHOS neurons eventually rupture and die, leaving behind their aggregated contents as the extracellular senile plaques characteristic of AD, strongly illustrating an "inside-out" etiology of plaque formation.[54]

Highly Vulnerable Neuronal Populations

Not all neuronal subtypes are equally susceptible to autophagic failure. Recent spatial mapping in AD mouse models (such as the AppNL-G-FxMAPT double knock-in) demonstrates selective regional vulnerability. Specifically, sleep-wake regulating neurons in the lateral hypothalamus (orexinergic neurons) and the noradrenergic neurons of the locus coeruleus experience severe cytoplasmic autophagic impediment extremely early in the disease process, well before significant amyloid deposition occurs in the cortex.[27] This localized, early-stage autophagic failure perfectly correlates with the early-stage sleep dysregulation and fragmentation that is a common, debilitating, and often predictive prodromal symptom in human AD patients.[27]

Glial and Vascular Vulnerabilities

Beyond microglia and neurons, the broader supporting cast of the CNS is deeply and fatally impacted by autophagic arrest:

1. **Astrocytes:** As the primary metabolic and trophic regulators of the brain, astrocytes rely heavily on autophagy to manage lipid mobilization and limit reactive oxygen species (ROS) production.[57] Autophagic failure in astrocytes leads to profound mitochondrial malfunction. This dysfunction drives the activation of the NF-κB pathway, leading to the

massive secretion of SASP components (such as IL-6 and IFNγ) that further poison surrounding oligodendrocytes and neurons, exacerbating tau hyperphosphorylation.[46]

2. **Oligodendrocytes:** Autophagy is essential for the generation, maintenance, and compaction of the myelin sheath. Genetic ablation of macroautophagy specifically in oligodendrocytes leads to an age-dependent surge in myelin thickness, abnormal myelin swelling, behavioral deficits, and severe seizures due to altered neuro-conduction.[58]
3. **Endothelial Cells (Blood-Brain Barrier):** The endothelial cells forming the blood-brain barrier (BBB) utilize autophagy to maintain homeostasis and regulate permeability. Under ischemic or hypoxic stress, autophagy acts protectively to scavenge ROS and stabilize the barrier. When autophagy fails or is pharmacologically inhibited in these endothelial cells, critical tight junction proteins—most notably Claudin-5 (Cldn5) and occludin—are aberrantly redistributed from the cellular membrane into the cytosol.[60] This internalization destroys the structural integrity of the BBB, leading to severe vascular leakage, brain edema, and the unregulated infiltration of neurotoxic systemic molecules and peripheral immune cells.[62]

Chapter 4: Reversing the Tide: Schwartz's Systemic Immunology Paradigm

Given the systemic collapse of proteostasis, the irreversible senescence of resident microglia, and the widespread vulnerability of the neuro-glial-vascular network, therapeutic interventions aimed solely at stimulating the endogenous brain parenchyma have proven insufficient. The groundbreaking research led by Michal Schwartz and her laboratory posits that the key to halting neurodegeneration lies outside the brain—in the strategic rejuvenation and mobilization of the peripheral immune system.[7]

The Failure of the Bone Marrow-Brain Axis

Schwartz's framework begins with the critical observation that AD is not merely a localized brain disease, but is accompanied by a profound dysfunction in systemic myelopoiesis (the generation of myeloid cells in the bone marrow). In models like the 5xFAD mouse, the chronic, systemic elevation of type I interferon (IFN-I)—originating from the cGAS-STING activation in the diseased brain and spilling into the systemic circulation—drives a maladaptive response in both the femur and skull bone marrow niches.[7]

This chronic IFN-I signaling forces hematopoietic stem cells (HSCs) out of their necessary quiescent state, pushing them into rapid cell cycling. Over time, this leads to the severe depletion and functional exhaustion of the long-term HSC (LT-HSC) compartment.[7] Consequently, the monocytes produced by this exhausted bone marrow are phenotypically impaired from birth. They fail to mature properly into anti-inflammatory phenotypes, exhibit abnormally high levels of the retention receptor CXCR4 (which prevents their proper release into the blood stream), and are transcriptionally biased toward a viral-like, pro-inflammatory

state.[7] Thus, precisely when the brain desperately requires peripheral reinforcements to clear amyloid and replace dying microglia, the peripheral immune system is crippled by the systemic echoes of the brain's own pathology, unable to answer the call.

Checkpoint Blockade: PD-L1 and the Recruitment of MDMs

To overcome this systemic failure, Schwartz's group utilizes immune checkpoint blockade, specifically targeting the programmed cell death protein 1 (PD-1) and its ligand (PD-L1) pathway. In cancer immunology, blocking PD-1 or PD-L1 removes the "brakes" from exhausted T-cells to attack tumors. In the context of neurodegeneration, Schwartz demonstrated that systemic administration of anti-PD-L1 blocking antibodies achieves a spectacular, disease-modifying dual effect.[7]

First, PD-L1 blockade acts as an immediate immune rejuvenator within the brain parenchyma. It rapidly facilitates the clearance of senescent microglia. Senescent cells in various tissues often upregulate PD-L1 on their surface as a "don't eat me" signal to evade immune surveillance; systemic anti-PD-L1 injection blocks this interaction, allowing for the rapid, selective elimination of senescent microglia through Fc-independent mechanisms.[25] This clears the toxic SASP environment, relieving the local neural tissue of constant inflammatory bombardment.

Second, and most critically, PD-L1 blockade modulates the brain-immune interface (specifically the choroid plexus) and restores peripheral immune dynamics, allowing for the massive recruitment and homing of Monocyte-Derived Macrophages (MDMs) from the blood, across the blood-cerebrospinal fluid barrier, and into the brain parenchyma.[7]

Therapeutic Reinforcements: Resident Microglia vs. Recruited MDMs

BIOLOGICAL CATEGORY	**Resident Senescent Microglia** Local CNS Environment	**Recruited MDMs** Post PD-L1 Blockade
Origin & Environment	COMPROMISED Resident innate immune cells of the CNS. Subjected to prolonged exposure to hostile stimuli within the chronic diseased brain environment.	FRESHLY MOBILIZED Arise from circulating monocytes replenished by hematopoietic stem cells in the bone marrow or spleen. Freshly recruited from blood circulation.
Autophagic Flux & Metabolism	IMPAIRED Suffer from severe metabolic impairment. Characterized by lipid-drop accumulation and increased production of Reactive Oxygen Species (ROS).	FUNCTIONAL Act as essential reinforcements possessing high clearance capacity, contributing to the restoration of microglial autophagy flux.
Phenotypic State	SENESCENT Exhausted and senescent due to aging and sustained activation. Exhibit heavily reduced patrolling activity in the brain tissue.	ACTIVE Adopt an inflammation-resolving phenotype, actively fostering tissue repair and not subjected to long-term local stimulation.
Key Markers	PATHOLOGICAL PROFILE Loss of homeostatic receptors (**P2RY12**, **TGFBR1**). Show increased expression of genes such as **TREM2**, **APOE**, **B2M**, and **CSF1**.	RESTORATIVE PROFILE Express unique scavenger molecules, particularly high levels of macrophage scavenger receptor 1 (**MSR1**), required for disease modification.
Phagocytic Capacity	DEFICIENT Fall short in containing damage; frequently fail to clear accumulating proteins and escalating debris in chronic conditions.	SUPERIOR Perform highly efficient phagocytosis, rapidly clearing cellular debris and misfolded protein aggregates (e.g., amyloid-beta).
Cytokine Profile	TOXIC Contribute to inflammatory exacerbation through increased and sustained production of pro-inflammatory mediators.	HEALING Release crucial anti-inflammatory factors, creating a microenvironment that is permissive to recovery and neural regeneration.

Following PD-L1 blockade, freshly recruited Monocyte-Derived Macrophages (MDMs) bypass the exhausted local environment. Unlike senescent resident microglia, MDMs exhibit robust autophagic capacity, express high levels of scavenger receptors (**MSR1**), and secrete inflammation-resolving cytokines.

Data sources: PubMed, Nature Neuroscience, ResearchGate

The Superiority of Monocyte-Derived Macrophages

The recruited MDMs are not simply direct replacements for microglia; they are functionally superior reinforcements.[7] Because they originate from the bone marrow and are freshly recruited from the systemic circulation, MDMs have not been subjected to the decades-long, chronic local stimulation of the toxic, amyloid-laden brain environment.[7] Therefore, their autophagic and lysosomal networks are robust and completely intact.

Upon entering the brain, these MDMs express a unique, highly active set of scavenger receptors, notably Macrophage Scavenger Receptor 1 (MSR1) and MRC1.[23] They engage in highly efficient phagocytosis of amyloid plaques, hyperphosphorylated tau, and general cellular debris.[7] Furthermore, unlike the pro-inflammatory SASP secreted by senescent microglia, MDMs secrete anti-inflammatory factors, including Interleukin-10 (IL-10) and transforming growth factor-beta (TGF-β), which actively dampens the residual neuroinflammation and promotes a microenvironment permissive to synaptic regeneration and neuronal survival.[7]

Crucially, Schwartz's research demonstrates that this MDM-mediated rescue operates independently of microglial TREM2 signaling. In transgenic tauopathy and amyloidosis models where TREM2 is completely knocked out (Trem2-/-), PD-L1 blockade still successfully orchestrates MDM recruitment and achieves significant cognitive improvement.[24] This is a profound finding: it confirms that peripheral immune rejuvenation can bypass the broken endogenous TREM2/microglial pathways entirely. By shifting the burden of clearance from the exhausted, senescent local microglia to fresh, autophagically competent peripheral macrophages, PD-L1 blockade offers a robust, systemic workaround to CNS proteostatic collapse.

Conclusion

The pathogenesis of neurodegenerative diseases can no longer be viewed exclusively through the microscopic lens of neuronal protein aggregation. It is, fundamentally, a systemic crisis of biological clearance and immune regulation. Autophagy failure within microglia acts as a central, catastrophic node in this crisis. When microglial lysosomes fail, these cells are transformed from the brain's innate immune sentinels into drivers of neuroinflammation, releasing TNF-α to actively suppress neuronal autophagic flux. As this failure compounds, microglia inevitably succumb to senescence, characterized by severe metabolic shifts, lipid accumulation, and toxic SASP secretion. The abandonment of the CNS by its primary defenders exposes expanding domains of vulnerability, eventually engulfing axonal transport systems, synapses, astrocytes, and the neurovascular unit in a wave of proteotoxicity and lysosomal membrane permeabilization.

However, recognizing neurodegeneration as a systemic immunometabolic failure opens profound new therapeutic avenues. The pioneering paradigm established by Michal Schwartz

provides a mechanistic blueprint for rescue that does not rely on fixing irrecoverably broken local cells. By recognizing that chronic brain inflammation exhausts the peripheral bone marrow, and by utilizing immune checkpoint blockade (PD-L1) to sever the chains of this peripheral immune exhaustion, the brain can be reinforced from the outside. The strategic mobilization of highly functional, autophagically competent monocyte-derived macrophages circumvents the irreversible senescence of resident microglia. This systemic immunology approach proves that while the central nervous system may lose its internal battle against proteotoxicity, the mind can be decisively rescued by the rejuvenation and recruitment of the peripheral immune system.

Works cited

1. Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging - MDPI, accessed February 19, 2026, https://www.mdpi.com/1422-0067/18/3/598
2. Mechanisms of autophagy–lysosome dysfunction in neurodegenerative diseases - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12239022/
3. Impaired Microglia Autophagy in Neurodegenerative Diseases - Biospective, accessed February 19, 2026, https://biospective.com/resources/microglia-autophagy-neurodegenerative-diseases
4. Autophagy and Microglia: Novel Partners in Neurodegeneration and Aging - PMC - NIH, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC5372614/
5. Microglial autophagy in Alzheimer's disease and Parkinson's disease - PMC - NIH, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9872664/
6. Monocyte-derived macrophages act as reinforcements when microglia fall short in Alzheimer's disease - PubMed, accessed February 19, 2026, https://pubmed.ncbi.nlm.nih.gov/39762659/
7. A single injection of anti-PD-L1 blocking antibody induces.pdf
8. Microglia and Aging: The Role of the TREM2–DAP12 and CX3CL1-CX3CR1 Axes - MDPI, accessed February 19, 2026, https://www.mdpi.com/1422-0067/19/1/318
9. Autophagy enables microglia to engage amyloid plaques and prevents microglial senescence - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10950302/
10. Alzheimer's Disease Pathogenesis: Role of Autophagy and Mitophagy Focusing in Microglia, accessed February 19, 2026, https://www.mdpi.com/1422-0067/22/7/3330
11. Beyond Support Cells: Astrocytic Autophagy as a Central Regulator of CNS Homeostasis and Neurodegenerative Diseases - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12428568/
12. When Autophagy Stops, Microglia Sour into Senescence | ALZFORUM, accessed February 19, 2026, https://www.alzforum.org/news/research-news/when-autophagy-stops-microglia-sour-senescence

13. Microglia, Trem2, and Neurodegeneration - PMC - NIH, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11576490/
14. Microglial autophagy in neurogenesis: a new player in Alzheimer's disease - Semantic Scholar, accessed February 19, 2026, https://pdfs.semanticscholar.org/732f/4f74c331841aa637f02ae175a5f0cf7acb26.pdf
15. TREM2-dependent senescent microglia conserved in aging and Alzheimer's disease - bioRxiv, accessed February 19, 2026, https://www.biorxiv.org/content/10.1101/2023.03.20.533401v1.full.pdf
16. Autophagy at the synapse, an early site of dysfunction in neurodegeneration - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10035630/
17. Enhancing autophagy mitigates LPS-induced neuroinflammation by inhibiting microglial M1 polarization and neuronophagocytosis - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11882556/
18. Boosting peripheral immunity to fight neurodegeneration in the brain - PubMed, accessed February 19, 2026, https://pubmed.ncbi.nlm.nih.gov/39358094/
19. Systemic inflammatory cells fight off neurodegenerative disease - PubMed, accessed February 19, 2026, https://pubmed.ncbi.nlm.nih.gov/20531383/
20. How Do Immune Cells Support and Shape the Brain in Health, Disease, and Aging?, accessed February 19, 2026, https://www.jneurosci.org/content/33/45/17587
21. Microglial MHC-I induction with aging and Alzheimer's is conserved in mouse models and humans - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10643718/
22. Harnessing monocyte-derived macrophages to control central nervous system pathologies: no longer 'if' but 'how' - PubMed, accessed February 19, 2026, https://pubmed.ncbi.nlm.nih.gov/23007711/
23. PD-1/PD-L1 checkpoint blockade harnesses monocyte-derived macrophages to combat cognitive impairment in a tauopathy mouse model - PubMed, accessed February 19, 2026, https://pubmed.ncbi.nlm.nih.gov/30692527/
24. Alzheimer's disease modification mediated by bone marrow-derived macrophages via a TREM2-independent pathway in mouse model of amyloidosis - Weizmann Institute of Science, accessed February 19, 2026, https://weizmann.elsevierpure.com/en/publications/alzheimers-disease-modification-mediated-by-bone-marrow-derived-m/
25. Michal SCHWARTZ | Professor | Professor | Weizmann Institute of Science, Rehovot | weizmann | Department of Neurobiology | Research profile - ResearchGate, accessed February 19, 2026, https://www.researchgate.net/profile/Michal-Schwartz-2
26. Identification of senescent, TREM2-expressing microglia in aging and Alzheimer's disease model mouse brain - PubMed, accessed February 19, 2026, https://pubmed.ncbi.nlm.nih.gov/38637622/
27. Autophagic impairment in sleep–wake circuitry is linked to sleep loss at the early stages of Alzheimer's disease - PMC, accessed February 19, 2026,

https://pmc.ncbi.nlm.nih.gov/articles/PMC12465791/
28. Role of microglia autophagy and mitophagy in age-related neurodegenerative diseases - Frontiers, accessed February 19, 2026, https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2022.1100133/full
29. Neuronal Autophagy Failure Drives α-Synuclein Transfer to Microglia to Outsource Aggregate Clearance - bioRxiv.org, accessed February 19, 2026, https://www.biorxiv.org/content/10.1101/2024.04.19.590207v2.full.pdf
30. How Microglia Manages Non-cell Autonomous Vicious Cycling of Aβ Toxicity in the Pathogenesis of AD - PubMed Central, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7718019/
31. Aging-related dysregulation of energy metabolism and mitochondrial dynamics in microglia, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12152248/
32. Molecular Regulation Mechanism of Microglial Autophagy in the Pathology of Alzheimer's Disease - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10389815/
33. A Critical Role of Autophagy in Regulating Microglia Polarization in Neurodegeneration, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6256089/
34. A Critical Role of Autophagy in Regulating Microglia Polarization in Neurodegeneration - PubMed, accessed February 19, 2026, https://pubmed.ncbi.nlm.nih.gov/30515090/
35. Microglial Modulation of Neuronal Autophagy: Uncovering Cytokine-Mediated Pathways, accessed February 19, 2026, https://www.repository.cam.ac.uk/items/cab9bfa5-356a-4684-bdf2-7b64eb89a3b1
36. A Critical Role of Autophagy in Regulating Microglia Polarization in Neurodegeneration, accessed February 19, 2026, https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2018.00378/full
37. Microglia rescue neurons from aggregate-induced neuronal dysfunction and death through tunneling nanotubes - PubMed, accessed February 19, 2026, https://pubmed.ncbi.nlm.nih.gov/39059388/
38. Neuronal Autophagy Failure Drives α-Synuclein Transfer to Microglia to Outsource Aggregate Clearance - bioRxiv.org, accessed February 19, 2026, https://www.biorxiv.org/content/10.1101/2024.04.19.590207v2.full-text
39. A Newly Identified Mechanism of Microglia in Alzheimer's Disease Opens Doors to New Treatment Targets - Mount Sinai, accessed February 19, 2026, https://reports.mountsinai.org/article/neuro2024-03-microglia-alzheimers-disease-yue-choi
40. A single injection of anti-PD-L1 blocking antibody induces a transient reduction in tau pathology in P301S (PS19) mouse model of tauopathy | bioRxiv, accessed February 19, 2026, https://www.biorxiv.org/content/10.1101/2025.09.28.679024v1
41. Emerging role of senescent microglia in brain aging-related neurodegenerative

diseases - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10877780/
42. Untangling senescent and damage-associated microglia in the aging and diseased brain - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC9167891/
43. Microglial Senescence and Neurodegenerative Diseases - Biospective, accessed February 19, 2026, https://biospective.com/resources/microglial-senescence-and-neurodegenerative-disease
44. Autophagy regulates cellular senescence by mediating the degradation of CDKN1A/p21 and CDKN2A/p16 through SQSTM1/p62-mediated selective autophagy in myxomatous mitral valve degeneration - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12283023/
45. Science Note: Senescence DOJINDO LABORATORIES, accessed February 19, 2026, https://www.dojindo.com/contents/sciencenote_Senescence.html
46. Neuroinflammaging and the Immune Landscape: The Role of Autophagy and Senescence in Aging Brain - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11799035/
47. Senescent Microglia: The Key to the Ageing Brain? - MDPI, accessed February 19, 2026, https://www.mdpi.com/1422-0067/22/9/4402
48. Publications | Schwartz Lab - Weizmann Institute of Science, accessed February 19, 2026, https://www.weizmann.ac.il/brain-sciences/labs/schwartz/publications
49. Association between ApoE and senescence markers (a) Pearson's... - ResearchGate, accessed February 19, 2026, https://www.researchgate.net/figure/Association-between-ApoE-and-senescence-markers-a-Pearsons-correlation-between-the_fig1_379924781
50. Abnormal accumulation of autophagic vesicles correlates with axonal and synaptic pathology in young Alzheimer's mice hippocampus - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC3249205/
51. Molecular Mechanism and Regulation of Autophagy and Its Potential Role in Epilepsy, accessed February 19, 2026, https://www.mdpi.com/2073-4409/11/17/2621
52. Neuronal Autophagy: Regulations and Implications in Health and Disease - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10778363/
53. Emerging Role of the Autophagy/Lysosomal Degradative Pathway in Neurodevelopmental Disorders With Epilepsy - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7082311/
54. Autophagy–lysosomal-associated neuronal death in neurodegenerative disease - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC11418399/
55. The wake- and sleep-modulating neurons of the lateral hypothalamic area demonstrate a differential pattern of degeneration in Alzheimer - bioRxiv.org, accessed February 19, 2026, https://www.biorxiv.org/content/10.1101/2024.03.06.583765v2.full.pdf
56. When the Locus Coeruleus Speaks Up in Sleep: Recent Insights, Emerging

Perspectives, accessed February 19, 2026, https://www.mdpi.com/1422-0067/23/9/5028
57. The Contribution of Astrocyte Autophagy to Systemic Metabolism - PMC - PubMed Central, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7177973/
58. Autophagy in neural stem cells and glia for brain health and diseases - PMC - NIH, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC10664120/
59. Non-cell autonomous autophagy in amyotrophic lateral sclerosis: A new promising target?, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12856966/
60. Autophagy Protects the Blood-Brain Barrier Through Regulating the Dynamic of Claudin-5 in Short-Term Starvation - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC6345697/
61. Autophagy alleviates hypoxia-induced blood-brain barrier injury via regulation of CLDN5 (claudin 5) - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC8526012/
62. Autophagy-mediated occludin degradation contributes to blood–brain barrier disruption during ischemia in bEnd.3 brain endothelial cells and rat ischemic stroke models - PMC, accessed February 19, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC7071658/
63. P-Glycoprotein Aggravates Blood Brain Barrier Dysfunction in Experimental Ischemic Stroke by Inhibiting Endothelial Autophagy - Aging and disease, accessed February 19, 2026, https://www.aginganddisease.org/EN/10.14336/AD.2022.0225
64. Systemic administration of PD-L1 blocking antibodies leads to removal of senescent microglia | bioRxiv, accessed February 19, 2026, https://www.biorxiv.org/content/10.64898/2025.12.22.695923v1
65. Systemic administration of PD-L1 blocking antibodies leads to removal of senescent microglia | bioRxiv, accessed February 19, 2026, https://www.biorxiv.org/content/10.64898/2025.12.22.695923v1.full-text
66. Monocyte-derived macrophages act as reinforcements when microglia fall short in Alzheimer's disease - ResearchGate, accessed February 19, 2026, https://www.researchgate.net/publication/387783221_Monocyte-derived_macrophages_act_as_reinforcements_when_microglia_fall_short_in_Alzheimer's_disease